Acorah Software Products - Accounts Production 16.1.300 false true false true No description of principal activity 5 October 2023 31 October 2024 31 October 2024 15189006 Dr Louise Weiss Mr Cole Robertson iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 15189006 2023-10-04 15189006 2024-10-31 15189006 2023-10-05 2024-10-31 15189006 frs-core:CurrentFinancialInstruments 2024-10-31 15189006 frs-bus:PrivateLimitedCompanyLtd 2023-10-05 2024-10-31 15189006 frs-bus:FilletedAccounts 2023-10-05 2024-10-31 15189006 frs-bus:Micro-entities 2023-10-05 2024-10-31 15189006 frs-bus:AuditExempt-NoAccountantsReport 2023-10-05 2024-10-31 15189006 frs-bus:Director1 2023-10-05 2024-10-31 15189006 frs-bus:Director2 2023-10-05 2024-10-31
Registered number: 15189006
Ogma Therapy Ltd
Unaudited Financial Statements
For the Period 5 October 2023 to 31 October 2024
Parry and Parry Limited
3 Wellington Court
Wellington Street
Cambridge
CB1 1HZ
Balance Sheet
Registered number: 15189006
31 October 2024
£
Current assets 5,617
Creditors: Amounts Falling Due Within One Year (5,890 )
NET CURRENT LIABILITIES (273 )
TOTAL ASSETS LESS CURRENT LIABILITIES (273 )
NET LIABILITIES (273 )
CAPITAL AND RESERVES (273 )

Notes

1. General Information
Ogma Therapy Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 15189006 . The registered office is Founders Factory (Level 7), 2 Arundel St Temple, London, WC2R 3DA.
2. Average Number of Employees
Average number of employees, including directors, during the period was: 2
2
For the period ending 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board
Dr Louise Weiss
Director
18/02/2025